| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Net income (loss) | -15,778,071 | -8,360,096 |
| Gain on related party investment tnf | - | 0 |
| Gain on related party investment qcls | 2,089,000 | - |
| Adjustment from accrued liabilities to warrant liabilities | -469,000 | 469,000 |
| Issuance costs series c preferred stock and warrants | 1,234,553 | - |
| Loss on issuance of series c preferred stock | 215,000 | - |
| Change in fair value of investment tnf | - | -2,839,000 |
| Gain on re-fair value of warrants | 106,000 | 106,000 |
| Change in fair value of warrants - tnf | - | -4,832,000 |
| Stock-based compensation | 120,984 | 60,492 |
| Unrealized loss on marketable equity securities | -165,126 | -104,463 |
| Change in fair value of warrant liabilities | -10,231,000 | 243,000 |
| Change in fair value of derivative liability | 302,000 | 0 |
| Change in fair value of convertible note receivable - femasys | 1,304,000 | 912,000 |
| Change in fair value of warrant asset femasys | -1,941,000 | -1,215,000 |
| Change in fair value of investment qcls | -5,210,000 | - |
| Change in fair value of warrants - qcls | 1,218,000 | - |
| Increase in prepaid expenses and other current assets | 279,388 | 14,421 |
| Increase (decrease) in accounts payable | 535,716 | 66,005 |
| Decrease in accrued expenses | -1,081,424 | -1,006,424 |
| Net cash and cash equivalents used in operating activities | -2,973,504 | -1,993,981 |
| Investment in preferred stock and warrants | 3,000,000 | 0 |
| Net cash and cash equivalents used in investing activities | -3,000,000 | 0 |
| Repurchase of common stock, net | 0 | 0 |
| Redemption of preferred stock | 0 | 0 |
| Net proceeds from issuance of series c convertible preferred stock | 6,268,866 | - |
| Accrued series c convertible preferred stock and dividends | 61,250 | - |
| Net cash and cash equivalents used in financing activities | 6,207,616 | 0 |
| Effect of currency rate exchange on cash and cash equivalents | -258 | 123 |
| Net increase (decrease) in cash and cash equivalents | 233,854 | -1,993,858 |
| Cash and cash equivalents at beginning of period | 15,172,163 | - |
| Cash and cash equivalents at end of period | 15,406,017 | - |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)